AKT1 and liver cancer: AKT, β-catenin and Notch are key oncogenic pathways that are frequently mutated or dysregulated in liver cancer.3 However, targeted therapies of these pathways so far have limited efficacy,4 in part due to our incomplete understanding of the relative contribution of inflammatory factors and their ability to collaborate with oncogenic pathways.